PDCD1 and neoplasm: This bispecific antibody can accumulate in the tumor microenvironment, effectively blocking both the PD-1 and VEGF pathways, inhibiting PD-1-mediated immunosuppression, and blocking tumor angiogenesis in the microenvironment (156, 157).